Charles River Laboratories International, Inc. (CRL) is a publicly traded Healthcare sector company. As of May 20, 2026, CRL trades at $156.24 with a market cap of $7.22B and a P/E ratio of -41.91. CRL moved +2.47% today. Year to date, CRL is -25.10%; over the trailing twelve months it is +8.71%. Its 52-week range spans $91.86 to $230.02. Analyst consensus is buy with an average price target of $205.38. Rallies surfaces CRL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes CRL SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $156.24 |
| Market Cap | $7.22B |
| P/E Ratio | -41.91 |
| EPS | $-3.70 |
| Dividend Yield | 0.00% |
| 52-Week High | $230.02 |
| 52-Week Low | $91.86 |
| Volume | 747.46K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.03B |
| Net Income | $-182.84M |
| Gross Margin | 0.00% |
10 analysts cover CRL: 0 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $205.38.